Efficacy of topiramate (Topamax) in epileptic patients of different ages

被引：3

作者：

Voronkova K.V. ^{[1
]}

Pylaeva O.A. ^{[1
]}

Petrukhin A.S. ^{[1
]}

机构：

[1] Department of Nervous Diseases, Faculty of Pediatrics, Russian State Medical University, Moscow

来源：

Neuroscience and Behavioral Physiology | 2007年 / 37卷 / 6期

关键词：

Age-related characteristics; Epilepsy; Topiramate (Topamax); Treatment;

D O I：

10.1007/s11055-007-0051-2

中图分类号：

学科分类号：

摘要：

The aim of the present work was to assess the efficacy and tolerance of topiramate (Topamax) in patients of different ages with different types of epilepsy. This agent was used as monotherapy and combined therapy in 114 patients (53 male, 61 female) of the following age groups: early childhood (16), preschool and school age (20), pubertal (16), young (23), adult (38), and elderly (1). Treatment produced complete clinical remission in 48% of patients and decreases in fit frequency by more than 50% in 44% of patients. In terms of remission, Topamax was more effective in adolescents, youths and adults than in younger children, and this pattern was also seen in the treatment of symptomatic epilepsy. Tolerance was good in patients of all groups, and cases of side effects (weight loss, irritability, allergic skin reactions, paresthesia) were occasional. © Springer Science+Business Media, Inc. 2007.

引用

页码：547 / 551

页数：4

共 15 条

[11]

Privitera M.D., Brodie M.J., Mattson R.H., Et al., Topiramate, carbamazepine and valproate monotherapy: Double-blind comparison in newly diagnosed epilepsy, Acta Neurol. Scand., 107, 3, pp. 165-175, (2003)

[12]

Rosenfield W.E., Sachedo R.C., Et al., Long-term experience with topiramate as adjunctive therapy and as monotherapy in patients with partial onset seizures: Retrospective survey of open-label treatment, Epilepsia, 38, SUPPL. 1, pp. 34-36, (1997)

[13]

Sachedo R.C., Patell R., Rehnam K.U., Long-term experience with topiramate monotherapy, Epilepsia, 38, 3, pp. 294-300, (1997)

[14]

Tassinari C.A., Et al., Double-blind, placebo-controlled trial of topiramate (600 mg daily) for the treatment of refractory partial epilepsy, Epilepsia, 37, pp. 763-768, (1996)

[15]

Wheless J.W., Neto W., Wang S., Topiramate, carbamazepine, and valproate in children with newly diagnosed epilepsy: A unique trial design, Neurology, 56, SUPPL. 3, (2001)

← 1 2 →